In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 7, 2012, Pages 1081-1090

  Zhou, Xikun ^a   Qiu, Ji ^a   Wang, Zhen ^a   Huang, Nongyu ^a   Li, Xiaolei ^a   Li, Qian ^a   Zhang, Yinbing ^a   Zhao, Chengjian ^a   Luo, Can ^a   Zhang, Nannan ^a   Teng, Xiu ^a   Chen, Zhongwen ^a   Liu, Xiao ^a   Yu, Xianlian ^a   Wu, Wenling ^a   Wei, Yu Quan ^a   Li, Jiong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Gelonin; Immunotoxin; Non small cell lung cancer (NSCLC)

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY RECOMBINANT GELONIN FUSION PROTEIN; GELONIN; IMMUNOTOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; AUTOPHAGY; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOTOXINS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; SINGLE-CHAIN ANTIBODIES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864334668     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1181-7     Document Type: Article

References (39)

1. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750-763 (Pubitemid 37328910)
2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) (2009) SEER Cancer statistics review, 1975-2007. National Cancer Institute, Bethesda
3. Baluna R, Sausville EA, Stone MJ, Stetler-Stevenson MA, Uhr JW, Vitetta ES (1996) Decreases in levels of serum Wbronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins. Clin Cancer Res 2(10):1705-1712 (Pubitemid 26356355)
4. Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J (2008) Phase II study of paclitaxel, carboplatin, and cetuximab as Wrst line treatment, for patients with advanced non-small cell lung cancer (NSCLC) results of OPN-017. J Thorac Oncol 3(11):1286-1292
5. Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-Wrst century. Nat Rev Drug Discov 2(1):52-62 (Pubitemid 37361624)
6. Brereton HM, Chamberlain D, Yang RC, Tea M, McNeil S, Coster DJ, Williams KA (2007) Single chain antibody fragments for ocular use produced at high levels in a commercial wheat variety. J Biotechnol 129(3):539-546 (Pubitemid 46560153)
7. Bruell D, Stocker M, Huhn M, Redding N, Kupper M, Schumacher P, Paetz A, Bruns CJ, Haisma HJ, Fischer R, Finnern R, Barth S (2003) The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 23(4):1179-1186
8. Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Muller J, Ischenko I, Fischer R, Finnern R, Jauch KW, Barth S (2005) Recombinant anti- EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 15(2):305-313
9. Bush T, Freeman D, Ogbagabriel S, Belmontes B, Kozlosky C, Baher A, Johnson C, Van G, Cerretti D, Radinsky R (2005) Activity of panitumumab alone and in combination with chemotherapy against mutant epidermal growth factor receptor (EGFr)-expressing non-small cell lung carcinoma (NSCLC) cell lines and xenografts. Clin Cancer Res 11(24):9047s-9047s
10. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG (2009) Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the Her2/neu Oncogene Product: in vitro and in vivo Studies. Cancer Res 69(23):8987-8995
11. Fish-Steagall A, Searcy P, Sipples R (2006) Clinical experience with anti-EGFR therapy. Semin Oncol Nurs 22(1 Suppl 1):10-19 (Pubitemid 43564197)
12. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I (2011) Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 71(20):6300-6309. doi:10.1158/0008- 5472.CAN-11-1374
13. Frankel AE, Woo J-H, Neville DM (2009) Immunotoxins Principles of Cancer Biotherapy. In: Oldham RK, Dillman RO (eds). Springer, Netherlands, pp 407-449. doi:10.1007/978-90-481-2289-9-11
14. Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R (2009) Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther 8(6):1536-1546
15. Herbst RS, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors-A new paradigm for cancer therapy. Cancer 94(5):1593-1611 (Pubitemid 34212655)
16. Karamouzis MV, Grandis JR, Argiris A (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama-J Am Med Assoc 298(1):70-82 (Pubitemid 47026772)
17. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, Schaller E, Herrmann I, Wolf A, Urbig T, Baeuerle PA, Kufer P (2010) T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS-and BRAF-mutated colorectal cancer cells. Proc Nat Acad Sci USA 107(28):12605-12610
18. Martinez-Torrecuadrada JL, Cheung LH, Lopez-Serra P, Barderas R, Canamero M, Ferreiro S, Rosenblum MG, Casal JI (2008) Antitumor activity of Wbroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther 7(4):862-873 (Pubitemid 351551039)
19. Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8(1):3-9 (Pubitemid 32520250)
20. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG (2005) The vascular-targeting fusion toxin VEGF(121)/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 7(10):912-920
21. Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, Gandhi V (2007) The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood 109(6):2557-2564 (Pubitemid 46425902)
22. Pastan I (2003) Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 52(5):338-341 (Pubitemid 36578027)
23. Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD (2011) Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 286(6):4165-4172. doi:10.1074/jbc.M110.186973
24. Presta L (2003) Antibody engineering for therapeutics. Curr Opin Struct Biol 13(4):519-525 (Pubitemid 37011458)
25. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, Henegouwen PMPV (2007) EYcient inhibition of EGFR signalling and of tumour growth by antagonistic anti- EGFR Nanobodies. Cancer Immunol Immun 56(3):303-317 (Pubitemid 46035901)
26. Rosenblum MG, Cheung LH, Liu YY, Marks JW (2003) Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused-to the toxin gelonin. Cancer Res 63(14):3995-4002 (Pubitemid 36917918)
27. Rossi A, Maione P, Gridelli C (2006) Cetuximab in advanced non-small cell lung cancer. Crit Rev Oncol Hematol 59(2): 139-149 (Pubitemid 44094110)
28. Schaffitzel C, Hanes J, Jermutus L, Pluckthun A (1999) Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J Immunol Methods 231(1-2):119-135 (Pubitemid 30394728)
29. Schmidt M, Reiser P, Hills D, Gullick WJ, Wels W (1998) Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin. Int J Cancer 75(6):878-884 (Pubitemid 28134113)
30. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5(2):147-159
31. Selbo PK, Sivam G, Fodstad O, Sandvig K, Berg K (2000) Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin. Int J Cancer 87(6):853-859. doi:10.1002/ 1097-0215(20000915)87:6<853:AID- IJC15>3.0.CO;2-0 (Pubitemid 30660566)
32. Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M (1997) Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin Cancer Res 3(3):339-345 (Pubitemid 27158056)
33. Smallshaw JE, Ghetie V, Rizo J, Fulmer JR, Trahan LL, Ghetie MA, Vitetta ES (2003) Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol 21(4):387-391 (Pubitemid 36397658)
34. Society AC (2010) Cancer Facts and Figures 2010. American Cancer Society, Atlanta
35. Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermalgrowth- factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4(7):397-406 (Pubitemid 36833681)
36. Stirpe FOS, Pihl A (1980) Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 255:6947-6953 (Pubitemid 11234436)
37. Stish BJ, Oh S, Vallera DA (2008) Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J Neuro-Oncol 87(1):51-61
38. Veenendaal LM, Jin HQ, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG (2002a) In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors (vol 99, pg 7866, 2002). Proc Nat Acad Sci USA 99(16):10941
39. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG (2002b) In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 99(12):7866-7871 (Pubitemid 34650971)